Esperion Therapeutics (ESPR) Price Target Lowered to $50 at Chardan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Esperion Therapeutics (ESPR) Has Notable New Fan at the FDA and Should Be Bought on Weakness - Barclays
June 11, 2015 2:21 PM EDTAfter losing 19% Wednesday amid labeling and other concerns arising from the PCSK9 FDA AdCom panel discussion, weakness in Esperion Therapeutics (NASDAQ: ESPR) is continuing today with stock off another 2.6%. Despite the weak stock action, many sell-side analysts have come out to defend the name. Barclays was the latest, and today brought with... More
Credit Suisse Defends Esperion Therapeutics (ESPR); Does Not See Impact from PCSK9 Panel
June 10, 2015 1:06 PM EDTCredit Suisse is the latest firm to come out in defense of Esperion Therapeutics (NASDAQ: ESPR), which fell more than 20% today following the PCSK9 panel discussion yesterday, which some viewed as cautious for the label.
Analyst Jeremiah Shepard said they do not... More
Alirocumab AdComm Net Positive for Esperion Therapeutics (ESPR) ETC-1002, Needham & Company Says
June 10, 2015 8:15 AM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and $130 price target on Esperion Therapeutics (NASDAQ: ESPR) following a read-through from Alirocumab AdComm, which they view as a net positive for ETC-1002.
Messer commented, "We walked away from the FDA advisory panel for... More
Esperion (ESPR), Amgen (AMGN) Shares Weaken Post-Market After Praluent Gets FDA Backing
June 9, 2015 5:39 PM EDT(Updated - June 9, 2015 5:49 PM EDT)
Esperion Therapeutics (NASDAQ: ESPR) shares declined after-hours Tuesday. Earlier an FDA panel voted to back Regeneron (NASDAQ: REGN) and Sanofi's (NYSE: SNY) PCSK9, Praluent. Shares of Amgen (NASDAQ: AMGN) are also trading down slightly.
... More